Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTSH in Post-thyroidectomy Differentiated Thyroid Cancer (Phase I/II, China)
CTR20190466Phase 2Completed
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of thyrotropin alfa in well-differentiated thyroid cancer (WDTC), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Mar 2019; status: completed.
02
Drugs
thyrotropin alfa
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on CTR20190466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190466.